Core Insights - HEALWELL AI Inc. is making significant strides in integrating its AI capabilities and software platforms, focusing on preventative care and enhancing its SaaS offerings [1][2][8] Integration and Commercial Progress - The company has successfully unified its Khure and Pentavere AI capabilities into a single AI engine powered by DARWEN™, which has improved operational and commercial scale [2][12] - HEALWELL is leveraging Orion Health's global sales distribution network to create new upsell and cross-sell opportunities, enhancing its commercial pipeline as it enters 2026 [2][4] Market Acceptance and Product Development - HEALWELL's AI-enhanced software platforms, including the next-generation Amadeus AI, are gaining traction in markets across Canada, the United States, Europe, and the Middle East [3][12] - The DARWEN™ AI platform continues to expand its disease-state coverage and has received recognition, including the Prix Galien award [5][12] Scientific Validation and Strategic Focus - The company is strengthening its credibility in applied healthcare AI through scientific publications and clinical collaborations, with four publications accepted in the fourth quarter of 2025 [6][12] - HEALWELL is actively pursuing portfolio simplification and evaluating strategic investments, including a $2 million investment in xAI, now part of SpaceX [7][12] Long-term Strategy - The company aims to position itself as a global AI and data science partner for life sciences companies and health systems, capitalizing on structural healthcare tailwinds [8][9]

Core Insights - HEALWELL AI and its subsidiary Orion Health have signed a Memorandum of Understanding (MoU) with Lean Business Services to explore digital health and AI solutions in the Middle East and global markets [2][8] - The collaboration aims to enhance population health outcomes and accelerate the adoption of AI in clinical workflows [5][9] Company Overview - HEALWELL AI is focused on preventative care through healthcare artificial intelligence, aiming to improve healthcare and save lives by early disease detection [12] - Lean Business Services is a leading digital health technology company in Saudi Arabia, supporting national digital transformation initiatives and interoperability in healthcare [3][11] - Orion Health specializes in health information exchange technology and has a strong presence in the Middle East, having deployed significant health information exchanges in the region [9] Collaboration Details - The MoU combines HEALWELL's AI capabilities, Lean's market leadership, and Orion Health's interoperability technology to co-develop and commercialize next-generation healthcare solutions [5][8] - Initial collaboration areas include enhancing population health strategies and integrating AI solutions into Saudi Arabia's National Platform for Health and Insurance Exchange Services (NPHIES) [8][9] Strategic Importance - The partnership aligns with Saudi Arabia's Vision 2030 healthcare objectives, aiming to create a connected, data-powered healthcare system [3][7] - The MoU was signed during the Global Health Exhibition in Riyadh, highlighting the significance of this collaboration in advancing healthcare innovation in the region [6][9]

Core Insights - HEALWELL AI Inc. has announced the global launch of AmadeusAI, which integrates with its DARWEN™ AI technology to enhance healthcare providers' capabilities in patient identification and data analysis [2][3] - The AmadeusAI platform is designed to improve clinical workflows by transforming clinical data into actionable insights, thereby enabling faster identification of at-risk patients and better population health management [2][3][4] Company Update - The integration of Orion Health's Amadeus platform with HEALWELL's AI technology marks a significant milestone, allowing healthcare providers to gain deeper insights from both structured and unstructured clinical data [2][3] - AmadeusAI is now available as an upgrade for existing Amadeus customers, highlighting the strategic benefits of the Orion Health acquisition [3][6] Product Features - AmadeusAI includes the SMARTSuite of AI tools, which consists of SMARTSearch, SMARTSummary, and SMARTIdentify, aimed at streamlining clinical workflows and enhancing patient care [3][4] - SMARTSearch allows clinicians to retrieve information using natural language across various records, while SMARTSummary synthesizes fragmented patient data into concise narratives [4] - SMARTIdentify focuses on proactive patient cohort identification and risk stratification, shifting care from reactive to preventive [4] Market Position - HEALWELL's AmadeusAI has been deployed in various healthcare systems globally, including the NHS in the UK and health networks in Canada, New Zealand, and Australia, serving over 150 million patients [5][6] - The company is actively engaging with health systems to explore proof-of-value opportunities for its AI components, aiming to demonstrate the efficiency and outcome improvements enabled by integrated AI [6]

早在2021年，Amazon的云计算业务就在奥克兰设立了旗舰办公室，并计划扩大在新西兰的业务，但当时尚未承诺在本 地兴建最先进的数据中心。 如今，靴子落地。 日前，新西兰总理Christopher Luxon透露，亚马逊将向新西兰投资75亿美元。 总理说，这笔投资"肯定会对我们的GDP产生影响"。 他说，此举将创造多达1000个就业机会，并带来"价值约110亿的GDP提升"。 Luxon表示，亚马逊是"全球最大的公司之一，市值可能超过一万亿美元，约为新西兰的三倍半"。 他指出，"像AWS这样的全球巨头对新西兰投下信任票，这可能是新西兰有史以来规模最大、且公开宣布的科技投 资。" AWS隶属美国科技巨头Amazon，主要通过云计算平台向企业提供200多种服务。 在新西兰，AWS的客户包括Air New Zealand、BNZ、卫生部、TVNZ、奥克兰大学、Xero、Vodafone、Sharesies、 Deloitte和Orion Health。 亚马逊将向新西兰投资75亿美元，将其旗下的Amazon Web Services（AWS, 亚马逊云服务）设立在新西兰。 这一消息发布前一天，新西兰政府刚刚宣布持有 ...

Core Insights - HEALWELL AI Inc. reported a record revenue growth of 645% in Q2-2025, achieving quarterly revenue of $40.5 million compared to $5.4 million in Q2-2024, primarily driven by the acquisition of Orion Health [4][7][8] - The company achieved its first positive Adjusted EBITDA of $1.9 million in Q2-2025, a significant improvement from an Adjusted EBITDA loss of $3.7 million in Q2-2024, reflecting strong operational fundamentals [4][7][8] - HEALWELL's strategy is focused on becoming a pure-play software and services company, divesting its clinical research and patient services business units to enhance its AI and data science offerings [3][4][5] Financial Highlights - Revenue for Q2-2025 was $40.5 million, a 645% increase from $5.4 million in Q2-2024, with the Healthcare Software business experiencing a 1,064% year-over-year increase [4][7][13] - Gross Profit reached $21.3 million in Q2-2025, up 764% from $2.5 million in Q2-2024, resulting in a Gross Margin of 52.5%, compared to 45.2% in Q2-2024 [7][8][13] - The company had $19 million in cash as of June 30, 2025, an increase from $9.4 million at the end of 2024, positioning it well for future growth and acquisitions [5][7] Business and Operational Highlights - The acquisition of Orion Health, completed on April 1, 2025, is expected to contribute approximately $100 million in annual SaaS and services revenue, enhancing HEALWELL's global reach and customer base [4][7][8] - HEALWELL's AI segment achieved revenues of $5.1 million in the first half of 2025, representing a 223% year-over-year growth [8] - The company has identified several potential tuck-in M&A opportunities as part of its growth strategy [3][4] Strategic Initiatives - HEALWELL is focusing on integrating its AI solutions into public and private health systems, leveraging existing customer bases to accelerate adoption [3][4] - The company officially entered the U.S. healthcare market on June 11, 2025, launching AI-enabled tools targeting health systems and life sciences organizations [7][8] - The Board of Directors is exploring strategic alternatives for the clinical research and patient services business units to streamline operations and focus on high-margin software and services [4][5]

Core Insights - HEALWELL AI Inc. has reported improved performance in its AI business units, with a focus on preventative care and the acquisition of the remaining interest in Pentavere Research Group Inc. [2][6] - The AI business segment is projected to exceed $5 million in revenues for the first half of 2025, marking a year-over-year increase of over 200% [3][6] Financial Performance - Preliminary revenues for the AI business segment are expected to surpass $5 million for the first six months of 2025, indicating a significant growth compared to the previous year [3][6] - Positive Adjusted EBITDA is anticipated for the AI business segment during the same period [3][6] Strategic Developments - HEALWELL has acquired the remaining 49% of Pentavere, achieving full ownership, which is expected to enhance integration within its AI business segment [6][11] - The acquisition was completed for an aggregate purchase price of approximately $13.98 million, satisfied through the issuance of shares [11] Leadership and Vision - James Lee, the new CEO, expressed confidence in the potential of the AI division and highlighted the opportunity to differentiate offerings and accelerate commercialization of AI products [5][10] - The company aims to integrate its AI and data science products into its software platforms to facilitate market adoption [8] Product and Market Focus - Pentavere's DARWEN™ platform is recognized for its role in patient identification and preventative care, validated by major healthcare systems [9][10] - The company emphasizes the urgent need for AI in healthcare to address challenges faced by global healthcare systems [10]

Core Viewpoint - HEALWELL AI is strategically expanding into the U.S. healthcare market following its acquisition of Orion Health, aiming to enhance preventative care through AI-driven insights and a robust health data infrastructure [3][4]. Company Overview - HEALWELL AI Inc. is a healthcare artificial intelligence company focused on preventative care, utilizing proprietary technology to improve healthcare outcomes through early disease detection [11]. - The company is publicly traded on the Toronto Stock Exchange under the symbol "AIDX" and on the OTCQX Market under "HWAIF" [11]. Strategic Expansion - The acquisition of Orion Health, which has over two decades of experience in the U.S. healthcare sector, provides HEALWELL with immediate credibility and reach in a complex market [4][6]. - HEALWELL has established dedicated teams in the U.S. and Canada to address the distinct regulatory and market dynamics of each region [5]. Technology and Offerings - HEALWELL plans to introduce a modular, FHIR-native repository alongside Orion's HL7-based data repository, supporting interoperability and real-time data sharing [7]. - The company will launch a suite of AI-enabled tools, including clinical search, summarization, and patient risk stratification, designed to integrate with existing clinical infrastructures [8][10]. Market Potential - The U.S. digital health market reached $160.4 billion in 2024 and is projected to grow at a 15.4% CAGR from 2025 to 2033, reaching $695.2 billion [8]. - HEALWELL views the U.S. market as a key focus area due to its size and complexity [8]. Partnerships and Growth Strategy - HEALWELL aims to deepen its U.S. market presence through strategic partnerships and mergers and acquisitions, focusing on capital allocation to support its mission of AI-driven preventative care [9]. - The company has established partnerships with life sciences organizations and is actively engaged with seven of the top ten largest pharmaceutical companies globally [9]. Leadership Insights - The incoming CEO, James Lee, emphasized the company's progress in integration and market strategies, highlighting significant growth opportunities and the potential for AI to improve patient outcomes [10].

Financial Data and Key Metrics Changes - The company achieved annual revenue of $919.7 million in 2024, an increase of 19% compared to the prior year [22] - Adjusted EBITDA for 2024 was $46.7 million, down from $113.4 million in 2023, impacted by revenue deferrals [24] - Net income for 2024 was $29.1 million, representing a 75% year-over-year growth [26] - Free cash flow attributable to shareholders was $49.3 million, an increase of 16% compared to the prior year [27] Business Line Data and Key Metrics Changes - The Canadian business experienced a 30% year-over-year growth, with adjusted EBITDA growing 22% to $56 million [28] - Circle Medical's revenue was negatively impacted by a deferral of $56.6 million due to billing practices, expected to be recognized in 2025 [11][12] - CRH Medical faced a revenue deferral of approximately $24.5 million due to a cybersecurity attack, with recognition dependent on future collections [20] Market Data and Key Metrics Changes - Patient visits totaled 5.7 million in 2024, a 32% year-over-year increase, with Canadian visits growing by 35% [32] - Total care interactions increased by 37% to over 8.7 million, reflecting strong organic growth [33] Company Strategy and Development Direction - The company plans to focus on leveraging product and corporate synergies, particularly in Canada, where it sees the strongest returns [34] - Guidance for 2025 includes expected annual revenue of between $1.4 billion and $1.45 billion, with adjusted EBITDA guidance of $190 to $210 million [35] - The company is pursuing a spin-out of WellSTAR, expected to be a publicly listed entity by early 2026, which will enhance its growth potential [56][60] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving record revenue, adjusted EBITDA, and free cash flow in 2025, despite challenges in the operating environment [89] - The company anticipates strong growth in its Canadian operations, targeting $800 million in revenues and $100 million in adjusted EBITDA by the end of next year [93] Other Important Information - The company has a strong balance sheet with cash and cash equivalents of $131.7 million as of December 31, 2024 [86] - The company is actively seeking strategic alternatives for Circle Medical and WISP, with ongoing discussions with prospective buyers [80] Q&A Session Summary Question: Can you describe the service obligation under IFRS that Circle Medical didn't meet? - Management indicated that the issue is administrative in nature, related to compliance with IFRS revenue recognition [103][104] Question: Can you provide some color on how you estimated the settlement amount related to the Circle Medical investigation? - Management stated that estimates were made with the help of advisors and were audited to ensure reasonableness [106][107] Question: Can you elaborate on the 70 plus opportunities and the deal value of $300 million? - Management clarified that the deal pipeline could range from $300 million to $500 million, depending on contract lengths and types of implementations [112][113] Question: Given the delayed revenue, have you made any changes to processes at Circle Medical? - Management does not anticipate long-term impacts but expects short-term growth to slow as compliance is reviewed [121][122] Question: What are the drivers behind the confidence in achieving your guidance? - Management highlighted elevated organic growth and a strong M&A pipeline as key drivers for confidence in achieving guidance [123][124] Question: Are there specific product sets at WellSTAR that scale better internationally? - Management believes that OceanMD has significant international potential due to its quality and product portfolio [127][128]